---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-135310"
form_type: "8-K/A"
ticker: "WW"
cik: "0000105319"
company_name: "WW INTERNATIONAL, INC."
filed_at: "2024-05-09T23:59:59+00:00"
generated_at: "2026-06-02T04:41:33.071342+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.3
calibrated_materiality_score: 0.3
confidence: "high"
source: SEC EDGAR
---

# WW International corrects Q1 subscriber metrics; Clinical subscribers overstated by 4k

## Summary
- Clinical End of Period Subscribers corrected to 87k from 91k; Total End of Period Subscribers to 4.004M from 4.008M.
- Clinical Paid Weeks corrected to 1.038M from 1.056M; Total Paid Weeks to 51.782M from 51.799M.
- Error stemmed from double-counting of subscribers transitioning between Clinical and other plans; reporting framework revised.
- No other financial information, including revenues and EPS, was affected.
- FY 2024 guidance reaffirmed: total subscribers 3.8-4.0M, Clinical subscribers 140k-160k, and expectation for subscription revenue growth.

## SEC filing metadata
- accession: 0001193125-24-135310
- form_type: 8-K/A
- ticker: WW
- cik: 0000105319
- company_name: WW INTERNATIONAL, INC.
- filed_at: 2024-05-09T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.3
- calibrated_materiality_score: 0.3
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/105319/000119312524135310/0001193125-24-135310-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/105319/000119312524135310/d808697d8ka.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-135310
- JSON: https://secwatch.observer/filing/0001193125-24-135310.json
- Plain text: https://secwatch.observer/filing/0001193125-24-135310.txt

## Key facts
- Earnings Releases
  WW INTERNATIONAL, INC. reported first quarter ended March 30, 2024 results: revenue $206.5 million, net income ($347.9), EPS ($4.39).
  - Period: first quarter ended March 30, 2024
  - Revenue: $206.5 million
  - Net income: ($347.9)
  - EPS: ($4.39)
  - Result: reported results
  source text: as applicable. No other information was incorrectly presented. • End of Period Subscribers of 4.0 million, including 87 thousand End of Period Clinical Subscribers • Revenues of $206.5 million • Gross margin of 66.7%; excluding the net impact of restructuring charges related to prior year restructuring plans, adjusted gross margin of 67.9% • Operating Loss of $269.3
  evidence_url: https://www.sec.gov/Archives/edgar/data/105319/000119312524135310/0001193125-24-135310-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.